Panorama Capital invests in passionate entrepreneurs building leading companies in life sciences and technology.
Key people at Panorama Capital.
Key people at Panorama Capital.
Panorama Capital is a venture capital firm founded in 2005 that invests primarily in life sciences and technology companies, focusing on supporting passionate entrepreneurs building market-leading companies. Their mission centers on fostering innovation and growth by providing not only capital but also hands-on, collaborative support leveraging their extensive operating and investing experience. The firm targets sectors including biotechnology, pharmaceuticals, healthcare, software, and mobile technologies, aiming to create lasting value and impact in these high-growth fields[2][3][4].
The firm’s investment philosophy emphasizes a deep commitment to the teams they back, valuing integrity, teamwork, and a shared passion for building great companies. Panorama Capital’s approach is highly collaborative, going beyond financial investment to actively support portfolio companies with strategic guidance. This model helps accelerate growth momentum for startups by combining capital with operational expertise, contributing positively to the broader startup ecosystem in life sciences and technology[2].
---
Panorama Capital was founded in 2005 in Campbell, California, by a team including Srinivas Akkaraju M.D., Ph.D., Christopher J. Albinson, Rodney A. Ferguson, J.D., Ph.D., Shahan D. Soghikian, and Damion E. Wicker, M.D. The founders brought together deep expertise in medicine, science, law, and investment, which shaped the firm’s focus on life sciences and technology. The idea emerged from their shared vision to back entrepreneurs who are passionate about innovation in these sectors. Over time, the firm has evolved to emphasize a hands-on, operator-first investment approach, supporting growth-stage companies with a strong thematic focus on healthcare and technology innovation[2][4].
---
---
Panorama Capital rides the ongoing trend of increased innovation and investment in life sciences and technology, sectors driven by rapid advances in biotechnology, digital health, and software solutions. The timing is favorable due to growing global demand for healthcare innovation, personalized medicine, and technology-driven efficiencies. Market forces such as aging populations, rising healthcare costs, and digital transformation fuel the need for new solutions, positioning Panorama Capital to influence the ecosystem by enabling startups that address these critical challenges. Their active involvement helps bridge the gap between scientific innovation and commercial success, fostering a vibrant startup environment in these sectors[2][3].
---
Looking ahead, Panorama Capital is likely to continue leveraging its deep sector expertise and collaborative investment model to back emerging leaders in life sciences and technology. Trends such as AI in healthcare, gene editing, and digital therapeutics will shape their investment focus. As these fields evolve, Panorama’s influence may grow by helping startups navigate complex regulatory landscapes and scale innovations globally. Their commitment to partnership and operational support positions them well to remain a key player in driving technological and scientific breakthroughs that transform healthcare and technology markets[2].
This forward-looking approach ties back to their founding mission of supporting passionate entrepreneurs building leading companies that make a lasting impact.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 2, 2026 | Aerofugia | $144.0M Series C | CITIC Securities | CAS Star, Green Pine Capital Partners, Luminous Ventures (former Lightspeed China Partners), New Alliance Capital, Pan-Lin Capital, Vertex Ventures China, Yunsheng Capital |
